Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.10 EUR
Change Today +0.003 / 2.97%
Volume 0.0
LCLA On Other Exchanges
Symbol
Exchange
Indonesia
Munich
OTC US
OTC US
As of 5:03 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

kalbe farma tbk pt (LCLA) Snapshot

Open
€0.10
Previous Close
€0.10
Day High
€0.11
Day Low
€0.10
52 Week High
02/3/15 - €0.14
52 Week Low
10/13/14 - €0.09
Market Cap
4.9B
Average Volume 10 Days
3.9K
EPS TTM
--
Shares Outstanding
46.9B
EX-Date
05/26/15
P/E TM
--
Dividend
€19.50
Dividend Yield
1.26%
Current Stock Chart for KALBE FARMA TBK PT (LCLA)

Related News

No related news articles were found.

kalbe farma tbk pt (LCLA) Related Businessweek News

No Related Businessweek News Found

kalbe farma tbk pt (LCLA) Details

PT. Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades pharmaceutical products in Indonesia. It operates in four segments: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistics. The company offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, and CPG that are distributed to hospitals, pharmacies, and drug stores. It also provides over-the-counter drugs, energy drinks, ready-to-drink healthy beverage products, supplements, and other preventive products; nutritional products comprising powdered milk products for infants, toddlers, children, pre-teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs; and non-milk nutritional products. In addition, the company operates a retail health service, Mitrasana Clinics, an integrated clinic network consisting of physician’s general practice, pharmacies, laboratory, and health mart, which also offers hemodialysis services; contract services and resources, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products. Further, it offers health screening services; produces reagents; operates as an agent for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; markets and distributes ophthalmic products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as provides advertising services. PT. Kalbe Farma Tbk. was founded in 1966 and is headquartered in Jakarta, Indonesia.

12,474 Employees
Last Reported Date: 04/30/15
Founded in 1966

kalbe farma tbk pt (LCLA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kalbe farma tbk pt (LCLA) Key Developments

Kalbe Farma Revised Sales Guidance for the Year 2015

Kalbe Farma (Indonesia) revised sales outlook for the year 2015. For the period, the company cut its sales growth target to 7% from 11% year on year. The company also adjusted its annual revenue target to IDR 19 trillion (USD 1.42 billion). Initially the company expects full-year net sales growth of 11% to 13%.

Kalbe Farma Announces Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for 2015

Kalbe Farma announced earnings results for the first quarter of 2015. The company reported a 4.4% rise year on year in first-quarter net sales to IDR 4.2 trillion. For the first quarter of 2015, the company posted a 6.3% year on year rise in operating profit and a 7.2% increase in net profit to IDR 529 billion, mainly due to a wider gross profit margin (49.5% versus 47.8% a year earlier). For 2015, the company forecast full-year net sales growth of 11% to 13% year on year, net earnings growth of 14% to 16% year on year, and an operating profit margin of 16% to 17% year on year. It now forecasts full-year targets of 7% to 9% net sales growth and net earnings growth of 9% to 11% year on year. To company has budgeted IDR 0.9 trillion to IDR 1.1 trillion for capital expenditure aimed at expanding production and distribution capacity.

PT Kalbe Farma Tbk Presents at Indonesia Corporate day, Apr-21-2015

PT Kalbe Farma Tbk Presents at Indonesia Corporate day, Apr-21-2015 . Venue: Mandarin Oriental Hotel, Hong Kong.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LCLA:GR €0.10 EUR +0.003

LCLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LCLA.
View Industry Companies
 

Industry Analysis

LCLA

Industry Average

Valuation LCLA Industry Range
Price/Earnings 36.9x
Price/Sales 4.4x
Price/Book 7.8x
Price/Cash Flow 36.9x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KALBE FARMA TBK PT, please visit www.kalbe.co.id. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.